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Background: Wireless pH-monitoring is an accurate method for diagnosing adults with gastroesophageal reflux
disease (GERD). The aim of this study was to evaluate the use of the Bravo capsule on children investigated for
GERD in terms of safety, tolerability and feasibility before and after administration of proton pump inhibitors.
Methods: A Bravo capsule was inserted during upper endoscopy under general anaesthesia or deep sedation with
propofol. 48-hour pH-metry was performed in 106 children (50 males, 56 females) at the median age of 11 years
(range 17 months-18 years). On the second day of investigation, proton pump inhibitor (PPI) was given at a mean
dose of 1.6 mg/kg (SD ±0.6 mg). The definition of GERD was set to a reflux index (RI) of ≥5% and DeMeester score
(DMS) ≥14.7.
Results: Application of the capsule was successful in 103 of the 106 children (97.2%) and interpretable in 99 of
these 103 (96.1%). 49 of the children with interpretable results (49.5%) had GERD according to RI, while 51 (56.7%)
had GERD according to DMS. After PPI was given on day 2, RI decreased from a median of 4.9% (range 0.3-63.4%)
to 2.2% (0–58.0%), while DMS decreased from a median of 17.6 (range 2.2-207.6) to 8.2 (0.3-178.6), respectively
(p < 0.0001). No severe adverse events were reported.
Conclusion: Wireless pH-metry is a safe and tolerable method when investigating children for GERD. PPI given on
the second day of assessment provides additional information on response to treatment suggesting that pH-metry
preferably should be extended to 48 hours.Background
Gastroesophageal reflux disease (GERD) is defined as a
condition that develops when the reflux of stomach con-
tent into the esophagus causes troublesome symptoms
and/or complications [1]. The most common GERD
symptoms in adults are heartburn and regurgitation,
with esophageal complications such as reflux esophagitis,
hemorrhage, stricture, Barrett’s esophagus, and adenocar-
cinoma [1]. In children, GERD can also manifest as vomi-
ting, poor weight gain, failure to thrive, dysphagia, cough,
laryngitis, and wheezing [2,3]. It commonly occurs with
regurgitation in healthy children from birth; however only
4% of the infants have daily signs of reflux at one year of
age [4].* Correspondence: daniel.agardh@med.lu.se
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unless otherwise stated.Ambulatory 24-hour esophageal pH-metry with a
nasal wire system was previously considered the gold
standard in diagnosing GERD [5]. However, a nasal
catheter system is unpleasant for the patients and may
restrict reflux-provoking activities, resulting in falsely
lower values on pH-metry [6]. Therefore, a wireless sys-
tem was developed using a capsule attached to the mu-
cosa wall of the esophagus for electronic pH monitoring.
This so-called Bravo pH Monitoring System (Medtronic
Inc., Minneapolis, MN) has proven to be both safe and
tolerable in adults [7,8], as well as among children [9,10].
The possibility of ambulatory pH-metry also facilitates
diagnosing GERD [6]. In pediatric patients suspected to
have GERD of whom many may be neurologically im-
paired or have certain genetic disorders [11], it is even
more important to provide a less disturbing method for
pH-metry.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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for 48 hours [12]. By extending the measurement, the
investigation will be more robust to intra-assay varia-
tions of refluxes over time. Still, there is no consensus
whether a natural day to day variation of pH <4 should
be considered when testing for reflux as some studies
[13], but not others [14-17], demonstrate differences in
refluxes over longer periods. By using 48-hour ambula-
tory pH-monitoring, the second 24 hours could alterna-
tively be utilized to measure the effect of proton pump
inhibitors (PPI).
To date, PPI are considered the most effective medica-
tions in inhibiting gastric acid secretion and have shown
to decrease the number of reflux episodes in patients
with GERD [18]. In adult patients screened for GERD,
the wireless pH-monitoring system proved useful for
evaluating the reduction of acid exposure during PPI
medication given on the second day of measurement [19].
To the best of our knowledge, wireless pH-monitoring
system testing with and without PPI has not yet been eva-
luated in children.
The aim of this study was to compile the results of the
first 100 wireless pH-monitoring investigations per-
formed on children screened for GERD at our pediatric
gastroenterology unit in terms of feasibility, tolerability,
and safety. A second aim was to evaluate if a second
24 hours of pH-metry gained further information to the
diagnosis of GERD when the patient was given a high
dose of PPI.
Methods
A total of 106 children (50 males, 56 females) were con-
secutively screened for GERD with wireless pH-monitoring
at a median age of 11 years (range 17 months-18 years).
Patients were seen at the Department of Pediatrics between
February 23rd, 2010 and March 3rd, 2013, in collaboration
with the Unit of Endoscopy and the Department of Clinical
physiology, at the Skåne University Hospital in Malmö,
Sweden. All children were screened for clinical purposes of
suspected GERD and all parents gave their informed con-
sent to the investigation. Children on PPI medication were
advised to discontinue treatment at least two weeks prior
to the screening. The Skåne University Hospital research
advisory board approved the review of medical records in
accordance with the Declaration of Helsinki (SUS; 2013-
04-22).
Classification of GERD according to
esophago-gastro-duodenoscopy (EGD) and histopathology
Under general anesthesia or deep sedation with propofol
an EGD was performed and biopsies were taken from
the distal parts of the esophagus. Minor signs of non-
erosive esophagitis, such as shattered Z-line, increased
vessel signs or thickened mucus membrane, were notedand the mucosa were also classified into grades accord-
ing to the Los Angeles Classification regarding mucosal
breaks [20,21]. A pathologist analyzed the biopsies and
made a statement upon whether histological esophagitis
existed according to the Ismail-Beigi scale [22].
Application of the bravo capsule
During EGD, a Bravo pH Capsule (Medtronic Inc,
Shoreview, MI, USA) was placed approximately 5 centi-
meters above the lower esophageal sphincter after being
calibrated in buffer solution and activated by a magnetic
switch, all according to manufacturer’s instructions. The
capsule was attached to the esophageal mucosa by suction,
and then secured in place by a stainless steel pin through
the mucosa. The Bravo pH Capsule detects and transmits
information of 6-second periods of pH-recordings every
12 seconds. A Bravo pH Receiver kept up to a maximum
2.5 meter from the patient recorded pH levels for appro-
ximately 48 hours. The patient and caregivers were in-
structed to record in a diary the position of the body
(supine or upright), food intake, and symptoms through-
out the 48-hour period. The second day of examination,
the patients were instructed to be medicated with high
dose PPI.
Interpretation of pH recordings
The pH-measurements stored in the Bravo pH Recorder
were analyzed using commercially available software
(Polygram NET, SynMed Medical, Stockholm, Sweden).
The 48 hours of data were displayed in a graph. Total
number of reflux episodes (TRE), TRE under 5 minutes,
time of the longest reflux episode (RE), and reflux index
(RI) indicated by the percentage of time with pH <4, RI
in an upright position, and RI in supine position were
calculated. DeMeester score (DMS), a combination of
the six different parameters mentioned above, was also
calculated. This data, together with the symptoms re-
corded in the patient diary, were analysed for each the
24 hours during the 48-hour screening period. Data
from the first 24 hours were used to classify the patient
where limits of DMS ≥14.7 and RI ≥5% defined the pre-
sence of GERD.
Statistical analysis
The data was analyzed in SPSS Statistics version 21
(SPSS, Inc., Chicago, IL). Asymmetric continuous data
was presented with a median and range and analyzed
with the Mann–Whitney U test and Wilcoxon signed
rank test. A percentage of agreement, with kappa, was
calculated on the outcome between EGD, histology and
pH monitoring. Nominal data, as symptoms, were ana-
lyzed with McNemars test. A p-value <0.05 was consi-
dered statistically significant.
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Findings in EGD and histopathology
Of the 106 patients who underwent EGD, 61 (57.5%)
had normal findings and 45 (42.5%) had macroscopic
signs of esophagitis (Table 1). Biopsies from the esopha-
gus were sent for histopathological evaluation in 104 of
the 106 performed endoscopies (98.1%). Of these 104
children, 26 (25.0%) had esophagitis findings only in
EGD, 9 (8.7%) had microscopical esophagitis only, 17
(16.3%) had esophagitis according to EGD that were
confirmed by histology, and 52 (50%) children had normal
findings with both examinations. The percentage of agree-
ment between EGD and histology was 66.3% (κ = 0.26).
Attachment of the bravo capsule
In 3 of the 106 cases, capsules were not successfully at-
tached for pH-metry. The first capsule was detached
during the procedure, another capsule was inhibited due to
failure of the Bravo pH Receiver prior to the investigation,
and in the final case the capsule was not attached due to
severe esophagitis. Application of the Bravo capsule was
successful in the remaining 103 cases (97.2%) and attached
at a mean of 4.8 centimeters above the lower esophageal
sphincter (mean length of esophagus 34.1 cm).
Feasibility of pH-monitoring
A complete pH-monitoring was successful in 99 of the
103 (96.1%) children with successfully attached capsules.
There was one pH-measurement missing due to an error
in the data transfer. Data on pH-monitoring were further
excluded from three children; one child had a misplace-
ment of the capsule, the capsule was detached in the
second child, and the third child was continuing PPI during
the whole procedure. Due to database error DMS was lost
in 9 of the children with a complete pH-monitoring.Table 1 Outcome of upper endoscopy
Endoscopic finding N (%)
Minor signs of non-erosive esophagitis* 31 (30.7)





Columnar lined esophagus 6 (5.9)
Signs of hiatus hernia 1 (1.0)
Cardia insufficiency 1 (1.0)
Eosinofilic esophagitis 1 (1.0)
Normal 45 (45.6)
Footnote: Grading was performed according to the Los Angeles.
Classification. *Minor signs of non-erosive esophagitis were e.g. shattered
Z-line, increased vessel signs or thickened mucus membrane.pH-monitoring before PPI - Day 1
Of the 99 successful pH-monitoring measurements, the
median of RI was 4.9% (range 0.3-63.4) and 49 (49.5%)
children had RI ≥5%. The median of DMS was 17.6
(range 2.2-207.6) and 51 (56.7%) of the 90 children with
available data on DMS had a DMS ≥14.7. Of the 90 pa-
tients with data on DMS the percentage of agreement of
the patients with GERD according to RI and DMS was
90% (κ = 0.8). For the children with GERD according
to DMS, the median RI was 10.7% (range 3.7-63.4),
whereas the median DMS was 41.0 (range 17.9-207.6)
among the children with GERD according to RI. The
percentage of agreement between RI and EGD was 57.6%
(κ = 0.15), between DMS and EGD was 51.1% (κ = 0.04),
between RI and histology was 52.1% (κ = 0.03) and bet-
ween DMS and histology 48.3% (κ = 0.04), respectively.
Diaries on meal intake, symptoms and body posi-
tions were completed by 96 of the 99 children with
successful pH monitoring. From the 96 diaries, 87
children experienced one or more symptoms (Table 2)
whereas 33 of the 90 children and 44 of the 99 chil-
dren with successful pH monitoring, recorded one or
more symptoms without having GERD according to
DMS and RI, respectively.pH-monitoring after PPI - Day 2
Data on doses of PPI were available in 96 of the 99 chil-
dren with successful pH-monitoring and was at a mean
of 1.6 mg/kg (SD ±0.6). Data was missing in one case,
and two of the children were treated with substances
other than PPI and were therefore excluded from the
analysis. After PPI was given on day 2, the median RI was
2.2 (range 0–58) and DMS was median 8.2 (0.3-178.6).
There were a strong reduction of RI and DMS, 4.7% andTable 2 Most common symptoms from diary records
before (day 1) and after proton pump inhibitor (day 2)
from 99 children
Symptom Day 1 Day 2 p-value
N (%) N (%)
Stomach pain 31 (31.3) 32 (32.3) 1.00
Nausea 20 (20.2) 21 (21.2) 1.00
Chest pain 22 (22.2) 14 (14.1) 0.22
Reflux 20 (20.2) 10 (10.1) 0.40*
Vomiting 24 (24.2) 12 (12.1) 0.10*
Sore throat 15 (15.2) 7 (7.1) 0.18
Dysphagia 13 (13.1) 5 (5.1) 0.23
Burping 11 (11.1) 4 (4.0) 0.13
Water brash/Heartburn 8 (8.1) 4 (4.0) 0.22
Coughing 6 (6.1) 2 (2.0) 0.38
*after Bonferroni correction.
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spectively). Data on RI and DMS on days 1 and 2 are
shown in Figure 1. Of the 96 children with data on PPI
dosage, 94 also completed the diary on day 2 (Table 2). Of
the 77 children who reported one or more symptoms,
57 of 96 and 46 of 87 of these children with available
DMS did not have GERD according to RI and DMS,
respectively.
Tolerability and complications
Diaries were completed in 100 of 103 of the children
who underwent wireless pH-monitoring. In one patient
it was unclear if the recorded symptoms referred to the
first or the second day. This patient was excluded from
summoned symptoms (Table 2). Many patients recorded
more than one symptom, but no child experienced se-
vere symptoms that required intervention during the
procedure. One child vomited one hour after the capsule
placement, therefore no measurable values were regis-
tered. The same patient later vomited a small amount of
blood. No other complication was recorded.
Discussion
Through this retrospective study on children screened
for GERD using the wireless Bravo Capsule system at a
single pediatric unit, one can conclude that it is a safe
and tolerable method of pH-monitoring in children. No
severe adverse events was seen and no examination was
terminated due to experienced symptoms, which is in
line with previous studies performed on children [9,10].
The feasibility of the wireless pH-monitoring method was
96%, which is comparable to other studies reporting 97%








































Figure 1 Box plot of DeMeester score (DMS) and reflux index (RI) on
gastroesophageal reflux disease (GERD). GERD was defined as having aThe concordance between EGD and histology showed a
scarce agreement whereas these two methods were even
more discordant as compared with the wireless pH-
monitoring. A plausible explanation for the discrepancy
may be a biased evaluation by the pediatric gastroenter-
ologist performing the endoscopy leading to an over-
interpretation of esophagitis. Another reason for the
discordant results could be the classification of esophagitis
applied by the pathologist. Recent papers show that using
the Ismail-Beigi scale is insufficient to detect microscopic
esophagitis in some adult patients with non-erosive reflux
disease (NERD) [23,24]. It is thus possible that the agree-
ment between histology and endoscopy may have been
improved if the biopsies had been reassessed according to
the most recent guidelines.
Still, one third of the study cohort had no signs of
esophagitis in EGD or microscopically, but had a patho-
logical RI on pH-metry and would be misdiagnosed if
not having been examined with pH-metry. Owing to the
three methods included, children investigated in this
study therefore seemed to benefit from pH-metry that
caught the diagnosis in the majority of the patients includ-
ing those having NERD. On the other hand, using the
wireless Bravo Capsule system for pH-metry only records
acid reflux and it cannot exclude that non-acid reflux is
causing some symptoms. When using the multichannel
intraluminal impedance and pH (MII-pH) monitoring sys-
tem both acid and non-acid refluxes are analyzed, which
enables to reveal any sort of reflux related to symptoms
[25]. However, the disadvantage with the MII-pH method
is the use of catheter which may be an unpleasant experi-
ence for the patient with risk for disturbing the investiga-






































day 1 and day 2 in all patients, and in patients with and without
DMS ≥14.7 and a RI ≥5, respectively.
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were set to 5% and 14.7, respectively. However, to date
there are no standardized cutoff limits for wireless pH-
monitoring for RI and DMS in adults or in children. Pre-
vious applied limits for pH-monitoring with conventional
probes at 4.2% [26] for RI and 14.7 for DMS [27] corres-
pond to a RI of 5.3% in adults with the wireless system
[12]. For children, the likelihood of GERD is considered to
be strong if RI is >7% and probable between a RI of 3-7%
[28], whereas normal values for DMS in children has not
been established. The cutoff limit set to 5% in this study
was arbitrarily estimated. Therefore, further studies on
children are needed to define normal values and optimal
cutoff values for pathology in wireless pH-monitoring.
Today, many children are in general blindly treated with
a short period of PPI prior to screening with EGD and
pH-metry. A previous study clearly demonstrated that a
PPI test has a low predictive diagnostic value for GERD
[29]. The pH-monitoring in this study showed that 50% of
the patients exceeded RI of 5% and 57% exceeded DMS of
14.7, so that they could successfully be treated for GERD.
At the same time, approximately half of the children in
our study cohort did not have GERD. They probably
would have been treated with PPI with potential risks for
adverse effects if they had not been screened properly
[30]. In addition, significant costs due to long periods of
unnecessary PPI treatments can be avoided [31].
The effect of PPI has previously been documented in
children and adolescents examined with MII-pH moni-
toring [32]. In that study, measures before and after a
two-month medication period revealed significant reduc-
tion in RI and DMS as well as symptom improvement
despite the number of total reflux being unchanged. The
number of acid reflux decreased when the number of
non-acid or weakly acid reflux increased. By giving a
high dose PPI on day 2 in our study, we were also able
to demonstrate a strong reduction of both RI and DMS
after PPI was given to the children that were diagnosed
with GERD. This corresponds with another study of
adult patients on and off PPI during pH metry [19]. The
procedure with and without high dosage of PPI also en-
ables the investigator to select those individuals that do
not respond to ordinary doses of PPI and would instead
benefit from surgery.
On the other hand, there are some limitations for not
utilizing the measurement of crude pH on both days.
Due to the day-to-day variability in acid exposure there
is a small risk of missing some children for not being
screened for 48 hours under normal conditions [13].
Adult patients that differ in acid exposure from one day
to another seem to have a lower total esophageal acid
exposure than the patients that do not show variation in
reflux over time [33]. Another potential pitfall is the use
of anesthesia or deep sedation with propofol whenperforming the endoscopy. It cannot be disregarded that
the use of sedation may have an effect on the lower
esophagus sphincter function immediately after the pro-
cedure resulting in increased numbers of acid refluxes
on pH-metry the first hours of examination. There is
thus a potential risk that this subgroup of children could
have been misdiagnosed with GERD in the present
study. However, other parameters such as clinical signs
and GERD related symptoms in relation to body position
and meal intake were also studied in correlation to the
pH recordings that could also provide valuable informa-
tion to the diagnosis.
Interestingly, there was no apparent overall difference in
reported symptoms between children diagnosed with and
without GERD. No specific symptom was reduced on the
second day of investigation as a response to PPI. Among
the children without GERD according to pH-metry, three
of four children still suffered from some sort of symptom
during the first day of the examination. The most com-
mon recorded symptoms in this study were chest and
stomach pain. Chest pain and foreign body sensation due
to the capsule have previously been described [8,9,12].
Since we did not collect information on the children’s
symptoms prior to the study, no conclusion could be
drawn of whether some symptoms where caused by the
capsule. Yet, no patient experienced such severe pain that
the screening had to be interrupted by surgical or endos-
copical intervention. More importantly, no severe adverse
effects were reported of the method in our cohort. How-
ever, the risk of anesthesia and performing endoscopy with
biopsies cannot be disregarded [34]. It is therefore recom-
mended to reassure the safety of the method through fre-
quent evaluations.
Conclusions
This study shows that the Bravo Capsule system for
esophageal pH-monitoring is both safe and tolerable in
children. The overall feasibility was 96%, which is consid-
ered high from a single unit as compared to other studies.
By extending the pH-metry to 48 hours, the method offers
the possibility to study the dose effect of PPI on acidic
refluxes and effect on self-reported symptoms in patients
diagnosed with GERD. We therefore recommend that in
cases where pH-metry is needed, the Bravo Capsule wire-
less system is used as the standard screening method of
suspected GERD in children.
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